Suche
Mein Konto
New data confirms the benefits of Daxor's BVA-100 blood test for heart failure patients
Daxor Corporation, the global leader in blood volume measurement technology, today announces new data validating the benefits of the company's BVA-100 blood test for patients with heart failure. The data were presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting (ASM) 2022, which brought together the world's leading heart failure experts in Washington, DC, September 30-October 3, 2022. This study demonstrates the significant benefit of BVA-led care for Medicare patients with heart failure. Reducing the mortality rate by 81% on a 30-day basis and 85% on a one-year basis (from 36.8% to 5.6%) for one of the leading causes of death...
New data confirms the benefits of Daxor's BVA-100 blood test for heart failure patients
Daxor Corporation, the global leader in blood volume measurement technology, today announces new data validating the benefits of the company's BVA-100 blood test for patients with heart failure. The data were presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting (ASM) 2022, which brought together the world's leading heart failure experts in Washington, DC, September 30-October 3, 2022.
This study demonstrates the significant benefit of BVA-led care for Medicare patients with heart failure. Reducing mortality rates by 81% on a 30-day basis and 85% on a one-year basis (from 36.8% to 5.6%) for one of the leading causes of death in the United States was shown to be achievable with BVA in this 216-patient study. The study also showed a 56% lower 30-day rehospitalization rate, indicating a strong economic benefit for payers.”
Jonathan Feldschuh, scientific director
“Understanding the impact of treatment decisions on outcomes for the 65-plus population is important to U.S. healthcare because Centers for Medicare & Medicaid Services (CMS) decisions regarding reimbursement, outcomes-based incentives and penalties for healthcare providers, and indication policies have an enormous impact on how healthcare is delivered,” said John E. Strobeck, MD, PhD, principal investigator.
The study, titled “Heart Failure Outcomes with Volume-guided Management in an Over-65 Population,” showed that this cohort of patients had significantly better outcomes compared to controls in 30-day readmissions (12.0% vs. 27.0%, P < 0.001), 30-day mortality (2.3% vs. 11.8%, P < 0.001) and 365-day mortality rates (5.6% vs. 36.8%, P < 0.001).
Source:
.